Patients with diabetic macular edema (DME) who did not adhere to intravitreal aflibercept therapy had significantly worse visual outcomes compared to patients who adhered to treatment, according to a study.
Of the 200 patients included in this study, 51% (n = 51%) adhered to intravitreal aflibercept therapy and follow-up. Significant decrease in visual acuity was noted in 47% of patients lost to follow-up who returned for further treatment after 48 months. In the adherent group and the return group, 1% and 17% developed proliferative diabetic retinopathy.
The authors concluded that patients who were lost to follow-up had 13 times great chance of developing a proliferative diabetic retinopathy.
Angermann R, Hofer M, Huber AL, et al. The impact of compliance among patients with diabetic macular oedema treated with intravitreal aflibercept: a 48-month follow-up study. Acta Ophthalmol. 2021;https://doi.org/10.1111/aos.14946